Biomarkers for Early Diagnosis of Acute Kidney Injury: Current Progress and Clinical Prospects

Title:Biomarkers for Early Diagnosis of Acute Kidney Injury: Current Progress and Clinical Prospects

Volume: 18 Issue: 12

Author(s): Hong-Feng Huang, Jing-Yi Zhou and Jiang-Hua Chen*

Affiliation:

• Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Qingchun Road 79, Hangzhou,China

Keywords: Acute kidney injury, biomarkers, cystatin C, IL-18, KIM-1, L-FABP, NGAL, NHE-3.

Abstract: Acute kidney injury (AKI) is one of the most common complications in critically ill patients, resulting in high morbidity and mortality. AKI usually occurs after major surgery, severe infection or drug-induced nephrotoxicity and is associated with prolonged hospital stays, increased costs and adverse clinical outcomes. The diagnosis of AKI is currently based on decreased glomerular filtration rate (GFR) and urine output, and increased serum creatinine. Novel biomarkers are required for early identification of patients with AKI to allow timely therapy and improve patient outcomes. With the advent of proteomics and genomics techniques, a vast array of biomarkers are now available in clinical practice.

Cite this article as:

Huang Hong-Feng , Zhou Jing-Yi and Chen Jiang-Hua *, Biomarkers for Early Diagnosis of Acute Kidney Injury: Current Progress and Clinical Prospects, Current Protein & Peptide Science 2017; 18 (12) . https://dx.doi.org/10.2174/1389203717666160909152205

DOI https://dx.doi.org/10.2174/1389203717666160909152205	Print ISSN 1389-2037
Publisher Name Bentham Science Publisher	Online ISSN 1875-5550